Passage Bio ( (PASG) ) just unveiled an announcement.
On March 4, 2025, Passage Bio reported its financial results for the fourth quarter and full year 2024, highlighting significant advancements in its PBFT02 program for FTD-GRN patients. The company demonstrated promising interim data showing durable progranulin expression and early biomarker improvements, and it plans to expand its clinical trials to include FTD patients with C9orf72 gene mutations. Passage Bio also extended its cash runway into the first quarter of 2027 by adopting an outsourced analytical testing model and reducing operating expenses, positioning itself well for late-stage development and regulatory engagement.
More about Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company focused on developing one-time therapies for neurodegenerative diseases. Their lead product candidate, PBFT02, targets conditions like frontotemporal dementia by elevating progranulin levels to restore lysosomal function and slow disease progression.
YTD Price Performance: -37.59%
Average Trading Volume: 424,481
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $32M
Learn more about PASG stock on TipRanks’ Stock Analysis page.